Search results
Showing 1261 to 1275 of 1282 results for long term conditions
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in final draft guidance published today (23 March 2023).
NICE, RCGP and SIGN publish guideline on managing the long-term effects of COVID-19
NICE, the Royal College of General Practitioners (RCGP) and the Scottish Intercollegiate Guidelines Network (SIGN) have today (18 December 2020) published a guideline on the management of the long-term effects of COVID-19 (also known as Long COVID).
NICE recommend dapagliflozin for people with chronic kidney disease
Dapagliflozin belongs to a group of medicines called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.
NICE identifies improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
NICE ME/CFS guideline outlines steps for better diagnosis and management
NICE has today (29 October 2021) published its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
NICE extends consultation period for new quality standard on fetal alcohol spectrum disorder
NICE has today (20 August, 2020), released its draft quality standard on fetal alcohol spectrum disorder (FASD) for further public consultation.
NICE & SIGN announce latest rapid Covid-19 guideline will address Long Covid
NICE and the Scottish Intercollegiate Guidelines Network (SIGN) have today (5 October 2020) announced they will work with the Royal College of General Practitioners (RCGP) to develop a guideline on persistent effects of Covid-19 (Long Covid) on patients.
We have listened to concerns raised by patient groups about the application of our rapid COVID-19 critical care guideline.
The long-term safety and efficacy is inadequate on two procedures NICE is calling for further evidence on
The NHS should offer weight loss surgery to thousands more people in order to tackle an epidemic of type 2 diabetes, says NICE.
Use NICE quality standards to guide good quality social care, says CQC
Social care services should use NICE guidance and quality standards to help identify and define good quality care, according to the Care Quality Commission (CQC).
Procedure carried out on unborn babies with spina bifida could improve their neurodevelopment
Operations are set to start taking place in the NHS